SG10201505484RA - Formulations of rifaximin and uses thereof - Google Patents
Formulations of rifaximin and uses thereofInfo
- Publication number
- SG10201505484RA SG10201505484RA SG10201505484RA SG10201505484RA SG10201505484RA SG 10201505484R A SG10201505484R A SG 10201505484RA SG 10201505484R A SG10201505484R A SG 10201505484RA SG 10201505484R A SG10201505484R A SG 10201505484RA SG 10201505484R A SG10201505484R A SG 10201505484RA
- Authority
- SG
- Singapore
- Prior art keywords
- rifaximin
- formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36360910P | 2010-07-12 | 2010-07-12 | |
US41905610P | 2010-12-02 | 2010-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201505484RA true SG10201505484RA (en) | 2015-09-29 |
Family
ID=45469785
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013001458A SG186981A1 (en) | 2010-07-12 | 2011-07-12 | Formulations of rifaximin and uses thereof |
SG10201505484RA SG10201505484RA (en) | 2010-07-12 | 2011-07-12 | Formulations of rifaximin and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013001458A SG186981A1 (en) | 2010-07-12 | 2011-07-12 | Formulations of rifaximin and uses thereof |
Country Status (26)
Country | Link |
---|---|
US (4) | US20120077835A1 (en) |
EP (2) | EP2593463B1 (en) |
JP (1) | JP5943915B2 (en) |
KR (1) | KR101887004B1 (en) |
CN (1) | CN103228662B (en) |
AU (1) | AU2011279261B2 (en) |
BR (1) | BR112013000802B1 (en) |
CA (1) | CA2804635C (en) |
CR (1) | CR20130033A (en) |
DK (1) | DK2593463T3 (en) |
EA (1) | EA033370B1 (en) |
ES (1) | ES2801678T3 (en) |
GE (1) | GEP20227342B (en) |
HU (1) | HUE049986T2 (en) |
IL (1) | IL223725B (en) |
LT (1) | LT2593463T (en) |
MX (1) | MX345697B (en) |
MY (1) | MY165086A (en) |
NZ (1) | NZ605232A (en) |
PL (1) | PL2593463T3 (en) |
PT (1) | PT2593463T (en) |
SG (2) | SG186981A1 (en) |
SI (1) | SI2593463T1 (en) |
TN (1) | TN2012000611A1 (en) |
WO (2) | WO2012009388A1 (en) |
ZA (1) | ZA201300193B (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1698630T3 (en) | 2005-03-03 | 2014-12-31 | Alfasigma Spa | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
ITBO20050123A1 (en) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA |
US9018684B2 (en) | 2009-11-23 | 2015-04-28 | California Institute Of Technology | Chemical sensing and/or measuring devices and methods |
IT1398550B1 (en) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | RIFAXIMINA COMPREHENSIVE FORMULATIONS USEFUL TO OBTAIN A PROLONGED EFFECT IN TIME |
ITBO20110461A1 (en) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS. |
CA2854380A1 (en) * | 2011-11-02 | 2013-05-10 | Salix Pharmaceuticals, Ltd. | Methods for treating irritable bowel syndrome (ibs) and infections |
CA2861104A1 (en) | 2012-01-25 | 2013-08-01 | Salix Pharmaceuticals, Ltd. | Rifaximin derivative and uses thereof |
ITBO20120368A1 (en) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | COMPOSITIONS INCLUDING RIFAXIMINA AND AMINO ACIDS, RIFAXIMINE CRYSTALS DERIVING FROM SUCH COMPOSITIONS AND THEIR USE. |
EP2757135B1 (en) | 2013-01-18 | 2017-11-29 | 3M Innovative Properties Company | Method of bonding parts to a vehicle by an acrylic foam tape |
WO2015069305A1 (en) * | 2013-11-08 | 2015-05-14 | Tyrx, Inc. | Antimicrobial compositions and methods for preventing infection in surgical incision sites |
WO2015171493A1 (en) | 2014-05-04 | 2015-11-12 | Salix Pharmaceuticals, Inc. | Ibs microbiota and uses thereof |
DK3143027T3 (en) | 2014-05-12 | 2019-08-12 | Alfasigma Spa | NEW SOLVATED CRYSTAL FORM OF RIFAXIMIN, PREPARATION, COMPOSITIONS AND APPLICATIONS THEREOF |
EP3307246A1 (en) | 2015-06-09 | 2018-04-18 | Capsugel Belgium NV | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
JP7024248B2 (en) * | 2016-09-01 | 2022-02-24 | 大正製薬株式会社 | Solid product |
RS63751B1 (en) | 2016-09-30 | 2022-12-30 | Salix Pharmaceuticals Inc | Solid dispersion forms of rifaximin |
EP3658123A4 (en) * | 2017-07-24 | 2021-04-28 | Acryspharm LLC | High drug loading pharmaceutical compositions |
CN109453165B (en) * | 2018-10-16 | 2021-02-05 | 丹诺医药(苏州)有限公司 | Solid dispersion of rifamycin-nitroimidazole coupled molecule and application thereof |
CN109453166B (en) * | 2018-10-16 | 2021-03-12 | 丹诺医药(苏州)有限公司 | Solid dispersion of rifamycin-quinolizinone coupled molecules and application thereof |
WO2020198136A1 (en) * | 2019-03-22 | 2020-10-01 | New York Medical College | Use of rifaximin on circulating aged neutrophils in sickle cell disease |
AU2020355603A1 (en) | 2019-09-24 | 2022-03-17 | Bausch Health Ireland Limited | Rifaximin liquid formulations |
US20230141118A1 (en) * | 2020-04-13 | 2023-05-11 | Bausch Health Ireland Limited | Methods of using solid dispersions of rifaximin for the treatment of sickle cell disease |
EP4171520A1 (en) | 2020-06-26 | 2023-05-03 | Bausch Health Ireland Limited | Targeted release rifaximin compositions |
US20230398102A1 (en) | 2020-10-29 | 2023-12-14 | Bausch Health Ireland Limited | Rifaximin liquid formulations for use inthe treatment of sickle cell disease |
CN114366717B (en) * | 2022-01-11 | 2023-06-09 | 四川农业大学 | Enteric solid dispersion particles based on EGCG nanoparticles, preparation method and application thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1154655B (en) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | IMIDAZO-RIFAMYCIN DERIVATIVES METHODS FOR THEIR PREPARATION AND USE AS AN ANTIBACTERIAL ACTION SUBSTANCE |
IT1199374B (en) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | PROCESS FOR THE PREPARATION OF PIRIDO-IMIDAZO-RIFAMICINE |
IT1320176B1 (en) | 2000-12-22 | 2003-11-26 | Nicox Sa | SOLID DISPERSIONS OF NITRATED ACTIVE INGREDIENTS. |
DE60220049T2 (en) * | 2001-06-22 | 2007-08-30 | Pfizer Products Inc., Groton | A pharmaceutical composition comprising a solid dispersion of a sparingly water soluble drug and a solubility enhancing polymer |
ITMI20032144A1 (en) * | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | REFLEXIMINE POLIMORPHIC FORMS, PROCESSES TO OBTAIN THEM AND |
US8974823B2 (en) * | 2003-12-31 | 2015-03-10 | Bend Research, Inc. | Solid compositions of low-solubility drugs and poloxamers |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
PL1698630T3 (en) | 2005-03-03 | 2014-12-31 | Alfasigma Spa | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
ITBO20050123A1 (en) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA |
US20080095754A1 (en) * | 2006-10-18 | 2008-04-24 | Burke Susan E | Ophthalmic compositions comprising diglycine |
AU2008273699A1 (en) * | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
EP2837378A1 (en) * | 2007-07-06 | 2015-02-18 | Lupin Limited | Pharmaceutical compositions of rifaximin |
KR100903618B1 (en) * | 2007-10-30 | 2009-06-18 | 삼성에스디아이 주식회사 | Plasma display panel |
US8067429B2 (en) * | 2008-02-25 | 2011-11-29 | Salix Pharmaceuticals, Ltd. | Forms of rifaximin and uses thereof |
US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
AU2009219240B2 (en) * | 2008-02-26 | 2014-10-16 | Salix Pharmaceuticals, Ltd. | Methods for treating bowel diseases |
EP2105130A1 (en) * | 2008-03-25 | 2009-09-30 | Ratiopharm GmbH | Pharmaceutical formula and method for its production |
WO2010067072A1 (en) * | 2008-12-10 | 2010-06-17 | Cipla Limited | Rifaximin complexes |
MY177151A (en) * | 2009-10-27 | 2020-09-08 | Lupin Ltd | Solid dispersion of rifaximin |
WO2011061748A1 (en) * | 2009-11-19 | 2011-05-26 | Strides Arcolab Limited | Rifaximin premix |
NZ602288A (en) * | 2010-03-10 | 2014-02-28 | Abbvie Bahamas Ltd | Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide |
-
2011
- 2011-07-12 PT PT118074186T patent/PT2593463T/en unknown
- 2011-07-12 EA EA201370018A patent/EA033370B1/en not_active IP Right Cessation
- 2011-07-12 HU HUE11807418A patent/HUE049986T2/en unknown
- 2011-07-12 JP JP2013519780A patent/JP5943915B2/en active Active
- 2011-07-12 AU AU2011279261A patent/AU2011279261B2/en active Active
- 2011-07-12 EP EP11807418.6A patent/EP2593463B1/en active Active
- 2011-07-12 US US13/181,481 patent/US20120077835A1/en not_active Abandoned
- 2011-07-12 WO PCT/US2011/043769 patent/WO2012009388A1/en active Application Filing
- 2011-07-12 SI SI201131898T patent/SI2593463T1/en unknown
- 2011-07-12 GE GEAP201112996A patent/GEP20227342B/en unknown
- 2011-07-12 KR KR1020137003493A patent/KR101887004B1/en active IP Right Grant
- 2011-07-12 BR BR112013000802-4A patent/BR112013000802B1/en active IP Right Grant
- 2011-07-12 PL PL11807418T patent/PL2593463T3/en unknown
- 2011-07-12 SG SG2013001458A patent/SG186981A1/en unknown
- 2011-07-12 ES ES11807418T patent/ES2801678T3/en active Active
- 2011-07-12 WO PCT/US2011/043767 patent/WO2012009387A1/en active Application Filing
- 2011-07-12 LT LTEP11807418.6T patent/LT2593463T/en unknown
- 2011-07-12 EP EP20172999.3A patent/EP3750526A1/en not_active Withdrawn
- 2011-07-12 CA CA2804635A patent/CA2804635C/en active Active
- 2011-07-12 NZ NZ605232A patent/NZ605232A/en unknown
- 2011-07-12 SG SG10201505484RA patent/SG10201505484RA/en unknown
- 2011-07-12 CN CN201180043828.XA patent/CN103228662B/en active Active
- 2011-07-12 MY MYPI2012005580A patent/MY165086A/en unknown
- 2011-07-12 DK DK11807418.6T patent/DK2593463T3/en active
- 2011-07-12 MX MX2013000522A patent/MX345697B/en active IP Right Grant
-
2012
- 2012-12-18 IL IL223725A patent/IL223725B/en active IP Right Grant
- 2012-12-19 TN TNP2012000611A patent/TN2012000611A1/en unknown
-
2013
- 2013-01-08 ZA ZA2013/00193A patent/ZA201300193B/en unknown
- 2013-01-23 CR CR20130033A patent/CR20130033A/en unknown
-
2014
- 2014-04-10 US US14/250,293 patent/US9737610B2/en active Active
-
2017
- 2017-06-06 US US15/615,121 patent/US20170333562A1/en not_active Abandoned
-
2020
- 2020-06-30 US US16/916,421 patent/US20200397904A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201300193B (en) | Formulations of rifaximin and uses thereof | |
HK1179608A1 (en) | Forms of rifaximin and uses thereof | |
IL250824B (en) | Certain amino-pyridazines, compositions thereof, and methods of their use | |
ZA201208770B (en) | New forms of rifaximin and uses thereof | |
EP2536756A4 (en) | Hsa-related compositions and methods of use | |
EP2584897A4 (en) | Resveratrol-containing compositions and methods of use | |
EP2603201A4 (en) | Liposome compositions and methods of use thereof | |
ZA201209259B (en) | Uses and compositions | |
EP2596112A4 (en) | Acetycysteine compositions and methods of use thereof | |
GB201006096D0 (en) | Novel compositions and uses thereof | |
EP2582664A4 (en) | Phenylthioacetate compounds, compositions and methods of use | |
SI2605757T1 (en) | Nalbuphine-based formulations and uses thereof | |
HRP20160922T1 (en) | Oligopeptidic compounds and uses thereof | |
IL227642A0 (en) | Forms of rifaximin and uses thereof | |
ZA201302952B (en) | Fungicidal compositions and methods of use | |
EP2566485A4 (en) | Immunostimulatory compositions and methods of use thereof | |
EP2552210A4 (en) | Formulations of mazindol | |
SI2407155T1 (en) | Formulations of inecalcitol | |
EP2637501A4 (en) | Fungicidal compositions and methods of use | |
HK1160777A1 (en) | Novel use of neohesperidoside | |
HU1000688D0 (en) | Use of trifluoro-phal | |
GB201019291D0 (en) | Compositions and uses | |
GB201020463D0 (en) | Herbicidal compositions and methods of use | |
GB201014319D0 (en) | Compounds and uses thereof |